Yuanmai Cell Announces Completion of First Patient Dosing in China's First Clinical Trial of Engineered Macrophage Therapy for Compensated Liver Cirrhosis

Recently, Nanjing Yuanmai Cell Biotechnology Co., Ltd. (hereinafter referred to as "Yuanmai Cell") has launched a new therapy for engineered macrophage treatment of compensated liver cirrhosis (MACF-001) at the Liver Disease Center and Infectious Disease Department of the General Hospital of the Eastern Theater Command.The project's clinical research has completed the enrollment and treatment of the first patient, and the safety follow-up has concluded. After receiving an infusion of engineered autologous macrophages, the patient did not exhibit significant adverse reactions, and various indicators such as inflammatory factors and liver function remained normal. Meanwhile, some indicators related to cirrhosis showed notable improvement. The study is continuing to recruit patients.

Nanjing Yuanmai Cell Biotechnology Co., Ltd. (hereinafter referred to as "Yuanmai Cell") is an innovative biotechnology platform company specializing in the research and development of macrophage immunotherapy drugs. It focuses on developing treatments for liver fibrosis and cirrhosis to address unmet clinical needs. The company has established proprietary intellectual property for anti-fibrotic technology.PayloadsHigh-throughput screening system,CARFunctional module library, in vitro gene editing system, and in vivo gene editing delivery system are the four core technology platforms. Through in vivo gene editing delivery technology, Yuanmai Cell advances the engineering transformation technology of macrophages from in vitro transfection technology to in vivo editing technology, achieving a leap from cell therapy technology to biopharmaceutical technology.

The Hepatology Center and Infectious Diseases Department of the General Hospital of the Eastern Theater Command is a large-scale, integrated military-civilian medical specialty that combines the diagnosis, internal medicine treatment, surgical treatment, prevention, rehabilitation, and research of liver and infectious diseases, with a focus on chronic hepatitis B.“Long-term Stability and Security”And“Clinical Cure”Radical direct-acting antiviral therapy for chronic hepatitis C, liver injury caused by various drugs such as anti-tumor medications, autoimmune liver diseases, fatty liver disease, alcoholic liver disease, hereditary metabolic liver diseases, liver failure, cirrhosis, tertiary prevention and diagnosis of primary liver cancer, internal and surgical management of liver transplantation, diagnosis, treatment, and prevention of various infectious diseases. The department has accumulated a profound theoretical foundation and extensive clinical experience in these areas. The specialty has nearly80The medical and nursing team of a person, including those with senior titles14The department boasts strong specialized medical and nursing capabilities. The current academic leader is Yu Lecheng. The department has a number of beds available.128Zhang, including the negative pressure ward (Artificial Liver and Blood Purification Treatment Center)/Severe Liver Disease and Infectious Disease Monitoring Center) beds20Zhang.   

To promote better mutual learning and communication, media platforms"WeChat Official Account 'Cell Gene Therapy' Team"A WeChat group for cell therapy and gene therapy discussions has been established. Interested friends can scan the QR code below to add the editor's WeChat and join the cell therapy and gene therapy discussion group.。